Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Advanced Search

Search

You could also try: reduce (1000), cut (225), diminish (17), lessen (22), decline (101), dwindle (2), reduction (689)

Southampton surgeons lead development of national hip surveillance programme

Description: Orthopaedic surgeons at Southampton Children’s Hospital are leading the development of a hip screening programme for children with cerebral pals
Url: /AboutTheTrust/Newsandpublications/Latestnews/2017/July-2017/Southampton-surgeons-lead-development-of-national-hip-surveillance-programme.aspx

Risk-reducing bilateral salpingo-oophorectomy - patient information

Description: This booklet explains what a risk-reducing bilateral salpingo-oophorectomy is and what the operation involves to help you decide whether
Url: /Media/UHS-website-2019/Patientinformation/Genetics/Risk-reducing-bilateral-salpingo-oophorectomy-1434-PIL.pdf

Carboplatin (AUC5) -Pegylated Liposomal Doxorubicin Retreat

Description: Chemotherapy Protocol GYNAECOLOGICAL CANCER CARBOPLATIN (AUC5) – PEGYLATED LIPOSOMAL DOXORUBICIN (Caelyx) Retreat Pl
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Ovarian-cancer/Carboplatin-AUC5-Pegylated-Liposomal-Doxorubicin-Retreat-Caelyx.pdf

Cyclophosphamide-Prednisolone-Rituximab- R-CP (21)

Description: Chemotherapy Protocol LYMPHOMA CYCLOPHOSPHAMIDE-PREDNISOLONE-RITUXIMAB (R-CP) Regimen • Lymphoma – R-CP (21)-Cyclophosphamide-Prednisolone-Rituximab Indication • Lymphoplasmacytic lymphoma/Waldenstrom’s
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Cyclophosphamide-Prednisolone-Rituximab-R-CP-21.pdf

Rucaparib

Description: A document based on Rucarib, an ovarian cancer condition.
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Ovarian-cancer/Rucaparib.pdf

Atezolizumab(1680-28days)

Description: Chemotherapy Protocol GENITOURINARY CANCER Atezolizumab (1680mg-28 days) Regimen • Urothelial– Atezolizumab (1680mg-28 days) Indication • This protocol was developed in response
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Bladdercancer/Atezolizumab1680-28days.pdf

InP-Ifosfamide-Liposomal Doxorubicin (Caelyx) v1

Description: Chemotherapy Protocol SARCOMA IFOSFAMIDE-LIPOSOMAL DOXORUBICIN (Caelyx) In-Patient Regimen Please note this proto
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Sarcoma/InP-Ifosfamide-Liposomal-Doxorubicin-Caelyx-v1.pdf

Cystic fibrosis diabetes - patient information

Description: This factsheet explains what to expect when you are tested for cystic fibrosis diabetes (CFD).
Url: /Media/UHS-website-2019/Patientinformation/Medicinestherapiesandanaesthetics/Cystic-fibrosis-diabetes-2635-PIL.pdf

Enfortumab-Vedotin-Pembrolizumab

Description: Chemotherapy Protocol UROTHELIAL CANCER Enfortumab vedotin-Pembrolizumab (EV-P) Regimen • Urothelial – Enfortumab vedotin - Pembrolizumab Indication • Firs
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Bladdercancer/Enfortumab-Vedotin-Pembrolizumab.pdf

Nursing and midwifery staffing report February 2026

Description: Report notes - Nursing and midwifery staffing hours - February 2026 Our staffing levels are continuously mo
Url: /Media/UHS-website-2019/Docs/About-the-Trust/performance/Nursing-and-midwifery-staffing-report.pdf

81 to 90 of 239

Previous … 7 8 9 10 11 … Next